The literature on the pharmacotherapy of Borderline Personality Disorder (BPD) is critically reviewed, and suggestions for the appropriate clinical use of psychotropic agents and directions for future research are made.
References
1.
GundersonJ.G.(A) Pharmocotherapy for patients with borderline personality disorder.Arch Gen Pyschiatry1986; 43: 698–700.
2.
ColeJ.O., SutherlandP.III, The drug treatment of borderline patients: In GrinspoonL (ed). Psychiatry 1982: Annual review.Washington: American Psychiatric Press Inc.,1982.
3.
Sarwer-FonerG.An approach to the global treatment of the borderline patient: psychoanalytic, psychotherapeutic and psychopharmacological considerations. In: HartocollisP., ed. Borderline personality disorders: the concept, the syndrome, the patient.New York: International Universities Press Inc.,1977: 345–364.
4.
LastU., LowenthalU., KleinH.: Borderline patients in a chronic ward.Arch Gen Psychiatry1973; 28: 517–521.
5.
ZetzelE.R.A developmental approach to the borderline patient.Am J Psychiatry1971; 127: 867–871.
6.
AakrogT.Conditions in adolescents who were borderline psychotics as children.Acta Psychiatr Scand1973; 49: 377–385.
7.
DyrudJ.E.The treatment of the borderline syndrome. In: OfferE., FreedmanD.X., eds. Modern psychiatry and clinical research.New York: Basic Books Inc.,1972: 159–173.
8.
FriedmanH.J.Some problems of inpatient management with borderline patients.Am J Psychiatry1969; 126: 299–304.
9.
HavensL.L.Some difficulties in giving schizophrenic and borderline patients medications.Psychiatry1968; 31: 44–50.
10.
AkiskalH.S.Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the borderline realm.Psychiatric Clin North Amer1981; 4: 25–46.
11.
AkiskalH.S., ChenS.E., DavisG.C.Borderline: an adjective in search of a noun.J Clin Psychiatry1985; 46: 41–48.
12.
AkiskalH.S., YerevanianB.I., DavisG.C.The nosologic status of borderline personality: clinical and Polysomnographic study.Amer J Psychiatry1985; 142: 192–198.
13.
KleinD.F.Psychopharmacology and the borderline patient. In: MackJ., ed. Borderline states in psychiatry.New York: Grune and Stratton,1975.
14.
KleinD.F.Psychopharmacological treatment and delineation of borderline disorders. In: HartcollisP., ed. Borderline personality disorders.New York: International Universities Press,1977.
15.
FinkM., PollackM., KleinD.F.Comparative studies of chlorpromazine and imipramine: I: drug discriminating patterns. In: BradleyP.B., FluegelF., HochP.H., eds. Neuropsychopharmacology.New York: Elsevier Publishing Co.,1964; Vol. 3: 370–372.
16.
HedbergD.L., HanchJ.H., GlueckB.L.Tranylcypromine – trifluoperazine combination in the treatment of schizophrenia.Am J Psychiatry1971; 127: 1141–1146.
17.
WinkelmanN.W.The Use of neuroleptic drugs in the treatment of nonpsychotic psychiatric patients. In: AydF., ed. Rational psychopharmacotherapy and the right to treatment.Baltimore: Ayd Medical Communications,1970.
BrinkleyJ.R., BeitmanB.D., FriedelR.O.Low-dose neuroleptic regimes in the treatment of borderline patients.Arch Gen Psychiatry1979; 36: 319–326.
20.
SoloffP.H.Pharmacotherapy of borderline disorders.Compr Psychiatry1981; 22: 535–543.
21.
LeoneN.F.Response of borderline patients to loxapine and chlorpromazine.J Clin Psychiatry1982; 43: 148–150.
22.
ColeJ.O., SalomonM., GundersonJ.Drug therapy in borderline patients.Compr Psychiatry1984; 25: 249–254.
23.
SerbanG., SiegelS.Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.Am J Psychiatry1984; 141: 1455–1458.
24.
GoldbergS.C., SchulzC., SchulzP.M.Borderline and schizotypal personality disorders treated with low dose thiothixene versus placebo.Arch Gen Psychiatry1986; 43: 680–686.
25.
SoloffP.H., GeorgeA., NathanR.S.Progress in pharmacotherapy of borderline disorders – a double blind study of amitriptyline, haloperidol and placebo.Arch Gen Psychiatry1986; 43: 691–697.
26.
CarrollB.J., GredenJ.F., FeinbergM.Neuroendocrine evaluation of depression in borderline patients.Psychiatr Clin North Amer1981; 4: 89–99.
27.
PopeH.G., JonesJ.M., HudsonJ.I., The validity of DSM-III borderline personality disorder.Arch Gen Psychiatry1983; 40: 23–30.
28.
SternbachH.A., FlemingJ., ExsteinI.The dexamethasone suppression and thyrotropin-releasing hormone tests in depressed borderline patients.Psychoneuroendocrinol1983; 8: 459–462.
29.
StoneM.H.The borderline syndromes: constitution, personality and adaptation.New York: McGraw-Hill International,1980.
30.
SpitzerR.L., WilliamsJ.B.W.Hysteroid dysphoria: an unsuccessful attempt to demonstrate its syndromal validity.Am J Psychiatry1982; 139: 1286–1291.
31.
LiebowitzM.R., KleinD.F.Interrelationship of hysteroid dysphoria and borderline personality disorder.Psychiatr Clin North Amer1981; 4: 67–87.
32.
CowdryR., GardnerD.Pharmacotherapy of borderline personality disorder.Arch Gen Psychiatry1988; 45: 111–119.
33.
GotliebI.H.Depression and general psychopathology in university students.J Abnorm Psychol1984; 93: 19–30.
34.
SoloffP.H., GeorgeA., NathanS.Paradoxical effects of amitriptyline on borderline patients.Am J Psychiatry1986; 143: 1603–1605.
35.
FaltusF.The positive effect of alprazolam in the treatment of three patients with borderline personality disorder.Am J Psychiatry.1984; 141: 802–803.
HallR.C.W., JoffeeJ.R.Aberrant response to diazepam: a new syndrome.Am J Psychiatry1972; 129: 738–742.
38.
IngramI.M., TimburyG.C.Side effects of librium.Lancet1960; (ii): 766.
39.
RosenbaumJ.F., WoodsS.W., GrovesJ.E.Emergence of hostility during alprazolam treatment.Am J Psychiatry1984; 141: 792–793.
40.
HermanJ.B., BrotmanA.W., RosenbaumJ.F.Rebound anxiety in panic disorder patients treated with short-acting benzodiazpines.J Clin Psychiatry (Suppl),1987; 48: 22–26.
41.
PostR.M., BallengerJ.C., UhdeT.W.Efficacy of carbarmazepine in manic depressive illness: implications for underlying mechanisms. In: PostR.M., BallengerJ.C., eds. Neurobiology of mood disorders.Baltimore: Williams and Wilkins,1984.
42.
PostR.M., UhdeT.S., Roy-ByrneP.P.Antidepressant effects of carbamazepine.Am J Psychiatry1986; 143: 29–34.
43.
DalbyM.A.Behavioural effects of carbamazepine.Adv Neurol1975; 11: 331–343.
44.
NeppeV.M.Carbamazepine as adjunctive treatment in non-epileptic chronic inpatients with EEG temporal lobe abnormalities.J Clin Psychiatry1983; 44: 236–331.
45.
MathisJ.A.Carbamazepine for uncontrolled rage outbursts.Lancet1984; ii: 1164–1165.
46.
GardnerD., CowdryR.Suicidal and parasuicidal behaviour in boderline personality disorder.Psychiatr Clin North Amer1985; 8: 389–403.
47.
GardnerD., CowdryR.Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder.Am J Psychiatry143: 519–522.
48.
GarnerD., CowdryR.W.Development of melancholia during carbamazepine treatment in borderline personality disorder.J Clin Psychopharmacol1986; 6: 236–239.
49.
CowdryR.W., DaviesR.K., PickarD.Limbic dysfunction in the borderline syndrome.Int J Psychiatr Med1985–86; 15: 201–211.
50.
AndrulonisP.A., GluckB.C., StroberC.F.Organic brain dysfunction and the borderline syndrome.Psychiatr Clin North Amer1981; 4: 47–66.
51.
JeffersonJ.W., GreistJ.H.Lithium carbonate and carbamaze-pine side effects. In: HalesR., FrancesA., eds. Psychiatry update, American Psychiatric Association, Annual Review, vol. 6.Washington: American Psychiatric Press Inc.,1987.
52.
KravitzH.M., FawcettJ.Carbamazepine in the treatment of affective disorders.Med Sci Res1987; 15: 1–8.
